Name | 3-[4-(pyridin-4-ylamino)phenyl]-4,5-dihydro-1H-pyridazin-6-one |
---|---|
Synonyms |
Senazodan
6-[4-(pyridin-4-ylamino)phenyl]-4,5-dihydropyridazin-3(2h)-one 3(2H)-Pyridazinone,4,5-dihydro-6-(4-(4-pyridinylamino)phenyl) 6-(4-(4-Pyridinylamino)phenyl)-4,5-dihydro-3(2H)-pyridazinone UNII-427L2I2KIM |
Description | Senazodan is a Ca2+ sensitiser, and also shows inhibition effect on PDE III. |
---|---|
Related Catalog | |
In Vitro | Senazodan seems to affect directly the actin-myosin crossbridge kinetics, and increase myosin ATPase activity[1]. Senazodan produces a concentration-dependent increase in tension development. Senazodan enhance Ca2+ binding to myofilaments and to purified cardiac troponin C. Senazodan also enhances contractility in guinea-pig papillary muscles by inhibiting PDE III[2]. |
References |
Density | 1.3g/cm3 |
---|---|
Molecular Formula | C15H14N4O |
Molecular Weight | 266.29800 |
Exact Mass | 266.11700 |
PSA | 73.10000 |
LogP | 1.57270 |
Index of Refraction | 1.677 |